{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:45:54Z","timestamp":1789580754818,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aims and background<\/jats:title>\n                    <jats:p>A number of population pharmacokinetic (PPK) models of anti-programmed cell death-1 (PD-1) monoclonal antibodies (mAbs) in multiple tumor types have been published to characterize the influencing factors of their pharmacokinetics. This review described PPK models of anti-PD-1 mAbs that investigate the magnitude and types of covariate effects in PK parameters, provide a reference for building PPK models of other anti-PD-1 mAbs, and identify areas requiring additional research to facilitate the application of PPK models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search for analyses of PPK models of eleven anti-PD-1 mAbs on the market that were carried out in humans was conducted using PubMed, Embase, and the Cochrane Library. The search covered the period from the inception of the databases to April 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Currently, there are fourteen analyses on PPK models of anti-PD-1 mAbs summarized in this review, including seven models that refer to nivolumab, four referring to pembrolizumab, one referring to cemiplimab, one referring to camrelizumab, and one referred to dostarlimab. Most analyses described the pharmacokinetics of anti-PD-1 mAbs with a two-compartment model with time-varying clearance (CL) and a sigmoidal maximum effect. The estimated CL and volume of distribution in the central (V\n                      <jats:sub>C<\/jats:sub>\n                      ) ranged from 0.179 to 0.290 L\/day and 2.98 to 4.46 L, respectively. The median (range) of interindividual variability (IIV) for CL and V\n                      <jats:sub>C<\/jats:sub>\n                      was 30.9% (8.7%\u201350.8%) and 29.0% (4.32%\u201340.7%), respectively. The commonly identified significant covariates were body weight (BW) on CL and V\n                      <jats:sub>C<\/jats:sub>\n                      , and albumin (ALB), tumor type, sex, and performance status (PS) on CL. Other less assessed significant covariates included lactate dehydrogenase (LDH), immunoglobulin G (IgG), ipilimumab coadministration (IPICO) on CL, and body mass index (BMI), malignant pleural mesothelioma (MESO) on V\n                      <jats:sub>C<\/jats:sub>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review provides detailed information about the characteristics of PPK models of anti-PD-1 mAbs, the effects of covariates on PK parameters, and the current status of the application of the models. ALB, BW, specific tumor type, sex, and PS should be considered for the future development of the PPK model of anti-PD-1 mAbs. Other potential covariates that were assessed less frequently but still have significance (e.g., LDH, IgG, and IPICO) should not be ignored. Thus, further research and thorough investigation are needed to assess new or potential covariates, which will pave the way for personalized anti-PD-1 mAbs therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.871372","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T12:35:49Z","timestamp":1663850149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jingyuan","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.714483","article-title":"Comparisons of underlying mechanisms, clinical efficacy and safety between anti-Pd-1 and anti-Pd-L1 immunotherapy: The state-of-the-Art review and future perspectives","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.08.005","article-title":"Induction of T cell anergy: Integration of environmental cues and infectious tolerance","volume":"22","author":"Chappert","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00789-7","article-title":"Immune checkpoint inhibitors in melanoma: A review of pharmacokinetics and exposure-response relationships","volume":"58","author":"Leven","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07831-9","article-title":"The landmark series: Non-melanoma skin cancers","volume":"27","author":"Lee","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1833857","article-title":"Tislelizumab: An investigational anti-Pd-1 antibody for the treatment of advanced non-small cell lung cancer (Nsclc)","volume":"29","author":"Liu","year":"2020","journal-title":"Expert Opin investigational Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: First global approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"mAbs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01539-5","article-title":"Dostarlimab: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01640-9","article-title":"Penpulimab: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01628-5","article-title":"Zimberelimab: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.003","article-title":"Pharmacokinetic\/Pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies","volume":"128","author":"Desnoyer","year":"2020","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006298360","article-title":"Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development","volume":"47","author":"Mascelli","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: A yin-yang balance","volume":"61","author":"Geraud","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01751","article-title":"Progress and challenges in the design and clinical development of antibodies for cancer therapy","volume":"8","author":"Almagro","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.656","article-title":"Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis","volume":"101","author":"Liu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.xphs.2018.10.064","article-title":"Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 longitudinal covariates in patients with non-small cell lung cancer","volume":"108","author":"Li","year":"2019","journal-title":"J Pharm Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1502","article-title":"Nivolumab clearance is stationary in patients with resected melanoma on adjuvant therapy: Implications of disease status on time-varying clearance","volume":"106","author":"Hamuro","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","article-title":"A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J immunotherapy Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e002344","DOI":"10.1136\/jitc-2021-002344","article-title":"Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors","volume":"9","author":"Hurkmans","year":"2021","journal-title":"J immunotherapy Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40262-021-01027-9","article-title":"Population pharmacokinetic models of vancomycin in paediatric patients: A systematic review","volume":"60","author":"Chung","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00963-2","article-title":"Population pharmacokinetics of levetiracetam: A systematic review","volume":"60","author":"Li","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13996","article-title":"Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology","volume":"85","author":"Bajaj","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03771-z","article-title":"Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers","volume":"83","author":"Osawa","year":"2019","journal-title":"Cancer chemotherapy Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1324","article-title":"Population pharmacokinetics and exposure - safety analyses of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma","volume":"59","author":"Wang","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1432","article-title":"Model-based population pharmacokinetic analysis of nivolumab in Chinese patients with previously treated advanced solid tumors, including non-small cell lung cancer","volume":"59","author":"Zhang","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12476","article-title":"Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies","volume":"8","author":"Zhang","year":"2019","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","article-title":"Model-based characterization of the pharmacokinetics of pembrolizumab: A humanized anti-Pd-1 monoclonal antibody in advanced solid tumors","volume":"6","author":"Ahamadi","year":"2017","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9528-y","article-title":"Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response","volume":"44","author":"Li","year":"2017","journal-title":"J Pharmacokinet pharmacodynamics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-021-09739-y","article-title":"Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies","volume":"48","author":"Yang","year":"2021","journal-title":"J Pharmacokinet pharmacodynamics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-00550-y","article-title":"Population pharmacokinetics of the anti-Pd-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy","volume":"42","author":"Wang","year":"2021","journal-title":"Acta pharmacologica Sin"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15339","article-title":"Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours","author":"Melhem","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20125","article-title":"Pharmacokinetic aspects of biotechnology products","volume":"93","author":"Tang","year":"2004","journal-title":"J Pharm Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: A new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr (Edinburgh Scotland)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070248","article-title":"Population pharmacokinetic studies in pediatrics: Issues in design and analysis","volume":"7","author":"Meibohm","year":"2005","journal-title":"AAPS J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e70703","DOI":"10.1371\/journal.pone.0070703","article-title":"Obesity impairs lymphatic fluid transport and dendritic cell migration to lymph nodes","volume":"8","author":"Weitman","year":"2013","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","article-title":"Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics","volume":"55","author":"Gill","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00874-2","article-title":"Pharmacokinetic variability of therapeutic antibodies in humans: A comprehensive review of population pharmacokinetic modeling publications","volume":"59","author":"Bensalem","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.61","article-title":"Racial\/Ethnic differences in drug disposition and response: Review of recently approved drugs","volume":"97","author":"Ramamoorthy","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2146\/ajhp140768","article-title":"Pembrolizumab and nivolumab: Pd-1 inhibitors for advanced melanoma","volume":"73","author":"Ivashko","year":"2016","journal-title":"Am J health-system Pharm AJHP Off J Am Soc Health-System Pharmacists"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-Mg\/Kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1821","article-title":"Clinical benefit-risk assessment of nivolumab 240 mg every 2 weeks in Chinese patients with advanced and metastatic solid tumors","volume":"61","author":"Sheng","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J immunotherapy Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01638-5","article-title":"Fixed dose of cemiplimab in patients with advanced malignancies based on population pharmacokinetic analysis","volume":"38","author":"Paccaly","year":"2021","journal-title":"Adv Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy408","article-title":"Assessment of nivolumab exposure and clinical safety of 480\u2009Mg every 4 weeks flat-dosing schedule in patients with cancer","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz037","article-title":"Model-informed drug development approach supporting approval of the 4-week (Q4w) dosing schedule for nivolumab (Opdivo) across multiple indications: A regulatory perspective","volume":"30","author":"Bi","year":"2019","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.015","article-title":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","volume":"31","author":"Zhao","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3527-6","article-title":"Safety profile of nivolumab administered as 30-Min infusion: Analysis of data from checkmate 153","volume":"81","author":"Waterhouse","year":"2018","journal-title":"Cancer chemotherapy Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12133","article-title":"Quantitative characterization of the exposure-response relationship for cancer immunotherapy: A case study of nivolumab in patients with advanced melanoma","volume":"6","author":"Wang","year":"2017","journal-title":"CPT: pharmacometrics Syst Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-0415","article-title":"Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/psp4.12477","article-title":"Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors","volume":"9","author":"Sanghavi","year":"2020","journal-title":"CPT: pharmacometrics Syst Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.871372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T12:35:52Z","timestamp":1663850152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.871372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2022.871372"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.871372","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"article-number":"871372"}}